Americans unhappy with drug prices

Caitlin Wilson | | Health Exec | Precision Medicine

Americans aren’t happy with a lot of things these days, including the prices of their prescription drugs, Fortune reported.

A survey from the Henry J. Kaiser Family Foundation in September found that 77 percent think prescription drug costs are too high. That figure is up from 72 percent who had the same complaint last year.

Forbes pointed out that the increased dissatisfaction could be abetted by the recent controversy surrounding drug-maker Mylan’s EpiPen price hike to up to $600 over the last 10 years.

On top of the general dissatisfaction with drug prices, 26 percent of those surveyed said they had a hard time paying for their own prescriptions and supported ideas for ways of reducing those costs.

Check out Fortune to see which ideas the Americans surveyed were most in favor of to reduce drug costs. 

More and More Americans Think Prescription Drug Costs Are 'Unreasonable'

Caitlin Wilson,

Senior Writer

As a Senior Writer at TriMed Media Group, Caitlin covers breaking news across several facets of the healthcare industry for all of TriMed's brands.

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.